Calling herself a “change agent,” GlaxoSmithKline Chief Executive Officer Emma Walmsley outlined plans to transform the pharmaceuticals business of GSK following the expected spin-off of the company’s consumer health division during an investor conference.
The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) to Merck for the company’s supplemental Biologics License Application for Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer.
Amgen is partnering with Ann Arbor, Michigan-based EVOQ Therapeutics for a license and collaboration deal to discover and develop drugs for autoimmune disorders.
Sanofi is lining up to spin off the active pharmaceutical ingredients division that will include a listing as a public company, Reuters reported, citing unnamed sources.
With a busy week for biotech quarterly and annual reports, here is a look at some of the top stories.
Merck is spinning off products from the company’s Women’s Health, Legacy Brands and Biosimilars businesses.
Pfizer Inc. reported a higher-than-expected third-quarter 2019 profit on increased sales of the cancer drug Ibrance and a strong launch of the new heart medicine Vyndaqel.
Novartis will officially spin its Alcon eye-care business off into a separately traded standalone business unit on April 9, 2019.
Mumbai-based Glenmark Pharmaceuticals is spinning off its innovation business into a U.S.-based standalone company.
Novartis’ eye care unit Alcon is withdrawing a surgical stent for glaucoma patients after clinical data showed it may damage the eye, but the Swiss drugmaker said the move would not affect plans to spin off the unit 2019.